Bradley Mark J. Gains Major Stake in Zoetis in 2023.

March 20, 2023

Trending News ☀️

In 2023, Bradley Mark J. has taken a giant step forward in his career, gaining a major stake in the pharmaceutical giant Zoetis Inc ($NYSE:ZTS). This is a major accomplishment for Bradley, who had previously been working in a lower position at the company. Bradley’s new position will give him the opportunity to play a major role in the future direction of Zoetis Inc. His knowledge of the pharmaceutical industry and management expertise will be invaluable in helping to guide the company’s strategic growth. He is well-suited for his new role, with years of experience in the industry and the ambition and drive to take Zoetis to the next level.

It is clear that Bradley is determined to make an impact on the company, and he is already setting his sights high. With his newfound power, Bradley is sure to lead Zoetis to greater heights, making it an even stronger presence in the pharmaceutical industry. His enthusiasm and ambition for the company are sure to be rewarded in the years to come.

Price History

On Monday, Bradley Mark J. announced his major acquisition of a stake in Zoetis Inc. This news is greeted with mostly positive sentiment as the company’s stock opened at $162.0 and closed at $163.4, up 1.2% from the previous closing price of $161.5. This indicates that investors are optimistic of the prospects of Zoetis Inc under the new ownership. The success of the acquisition will be watched closely by industry experts and investors alike. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Zoetis Inc. More…

    Total Revenues Net Income Net Margin
    8.08k 2.11k 27.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Zoetis Inc. More…

    Operations Investing Financing
    1.91k -883 -904
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    14.93k 10.52k 9.5
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Zoetis Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    8.9% 13.2% 35.6%
    FCF Margin ROE ROA
    16.4% 39.7% 12.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted an analysis of ZOETIS INC‘s wellbeing and assigned them a “Rhino” rating on our Star Chart. This indicates that the company has achieved moderate revenue or earnings growth. We believe that this type of company is of interest to investors that are looking for a moderate level of growth, but also a regular dividend. ZOETIS INC’s score is strong in dividend, growth, profitability, and medium in asset. The company’s health is also quite good with a score of 9 out of 10 when considering its cashflows and debt. This suggests that the company is capable of paying off debt and have enough cashflow to fund future operations. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.

    – BioGaia AB ($OTCPK:BIOGY)

    Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

    Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

    – Krka d.d. ($LTS:0HLK)

    Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.

    – Phibro Animal Health Corp ($NASDAQ:PAHC)

    Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.


    Investors have taken note of Bradley Mark J.’s major stake in Zoetis Inc., with the stock’s price rising and positive news coming out about the company. Analysts are looking at the long-term prospects of the company and their financials, which show a strong balance sheet with a good return on equity, low debt levels and a stable dividend. While Zoetis Inc. has seen some volatility in their stock in the past, analysts believe that the company is well-positioned to maintain their financial stability going forward and deliver strong returns to shareholders.

    Recent Posts

    Leave a Comment